NEW YORK (GenomeWeb) – Roche said today that it has acquired privately held CAPP Medical in order to develop technology for screening and monitoring cancer from circulating tumor DNA in blood.

CAPP Medical, based in Palo Alto, Calif., was founded in October 2013 by Stanford University oncologists and "industry veterans," according to Roche. Financial terms of the acquisition were not disclosed in the announcement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.